Video
Dr. Davies discusses data from CheckMate-274 study of nivolumab in urothelial carcinoma
Author(s):
"I think that for patients that have high-risk features after cystectomy, they absolutely should be on nivolumab. I don't think that's a controversial statement anymore," says Benjamin J. Davies, MD.
In this video, Benjamin J. Davies, MD, discusses findings from the study, Disease-free survival with longer follow-up from the CheckMate-274 trial of adjuvant nivolumab in patients after surgery for high-risk muscle-invasive urothelial carcinoma, which was presented at the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana. Davies is a professor of urology at the University of Pittsburgh School of Medicine, chief of urology at UPMC Shadyside, and program director of the Urologic Oncology Fellowship.
Related Videos
Related Content
